REFERENCES
1. Caputo V, De Falco V, Ventriglia A, et al. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. Ther Adv Med Oncol. 2022;14:17588359221096878.
2. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297-312.
3. Husain H, Pavlick DC, Fendler BJ, et al. Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples. JCO Precis Oncol. 2022;6:e2200261.
4. Basharat S, Farah K. An overview of comprehensive genomic profiling technologies to inform cancer care. Can J Health Technol. 2022;2:1-19.
5. Liu SC. Circulating tumor DNA in liquid biopsy: current diagnostic limitation. World J Gastroenterol. 2024;30:2175-8.
6. Nigro MC, Marchese PV, Deiana C, et al. Clinical utility and application of liquid biopsy genotyping in lung cancer: a comprehensive review. Lung Cancer. 2023;14:11-25.
7. Woodhouse R, Li M, Hughes J, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One. 2020;15:e0237802.
8. van der Leest P, Rozendal P, Rifaela N, et al. Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients. Commun Med. 2025;5:204.
9. Treichler G, Hoeller S, Rueschoff JH, et al. Improving the turnaround time of molecular profiling for advanced non-small cell lung cancer: outcome of a new algorithm integrating multiple approaches. Pathol Res Pract. 2023;248:154660.
10. Raez LE, Brice K, Dumais K, et al. Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC). Clin Lung Cancer. 2023;24:120-9.
11. Rolfo CD, Madison RW, Pasquina LW, et al. Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation. Clin Cancer Res. 2024;30:2452-60.
12. Romine PE, Sun Q, Fedorenko C, et al. Impact of diagnostic delays on lung cancer survival outcomes: a population study of the US SEER-medicare database. JCO Oncol Pract. 2022;18:e877-85.
13. Gálffy G, Morócz É, Korompay R, et al. Targeted therapeutic options in early and metastatic NSCLC-overview. Pathol Oncol Res. 2024;30:1611715.
14. Edsjö A, Holmquist L, Geoerger B, et al. Precision cancer medicine: concepts, current practice, and future developments. J Intern Med. 2023;294:455-81.
15. Gong J, Cho M, Fakih M. RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol. 2016;7:687-704.
16. Bartolomucci A, Nobrega M, Ferrier T, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol. 2025;9:84.
17. Al-Showbaki L, Wilson B, Tamimi F, et al. Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11:e005854.
18. Gouda MA, Huang HJ, Piha-Paul SA, et al. Longitudinal monitoring of circulating tumor DNA to predict treatment outcomes in advanced cancers. JCO Precis Oncol. 2022;6:e2100512.
19. Ma L, Guo H, Zhao Y, et al. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther. 2024;9:336.
